Equity research firms covering public U.S companies have a workforce of analysts dedicating their time covering the most popular stocks. Their reports are delivered to institutional investors in order to help make investment decisions. The information in these reports however can also be obtained by retail investors.
Analysts issue Buy, Sell and Hold recommendations as well as earnings estimates and guidance. Out of the 4 analysts covering shares of Stemline Therapeutics, Inc. (NASDAQ:STML), 5 rate it a “Strong Buy”, 0 rate it a “Buy”, 0 are advising to Hold the shares and 0 are saying “Sell”.
These recommendations can be transferred to a standard scale from 1 to 5. Combining all of the ratings, the current consensus is sitting at 1. A rating of 1 would be equivalent to a Strong Buy, and a rating of 5 would indicate a Strong Sell rating.
Let’s take a look at analyst target price estimates on the stock. The 4 analysts offering target price estimates on shares of Stemline Therapeutics, Inc. (NASDAQ:STML) have set a consensus target of $25.5 on shares. The standard deviation of all the estimates is currently $14.294. Target price projections may differ from analyst to analyst. The lowest price target is presently $11 and the analyst with the most aggressive opinion sees the stock going to $41.
The quarterly company earnings release is usually highly anticipated. Each quarter, investors and analysts wait to see the earnings numbers when they are posted for the public. The company is slated to next publish earnings on or around 2017-08-03. The current Wall Street consensus is expecting Stemline Therapeutics, Inc. (NASDAQ:STML) to report EPS of $-0.5 for the quarter. Analysts often update their models during the time leading up to earnings. The sentiment direction can be an important factor when trying to gauge where the Street sees the stock moving. Compared to the same quarter last year, the company reported earnings per share of $-0.52. After the most recent period, the company reported quarterly EPS of $-0.67 against the Zacks Research consensus estimate of $-0.47. This created a surprise factor of -42.55% or a numerical difference of $-0.2.
This article is for informational purposes only. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell Stemline Therapeutics, Inc..